A5031507252- Brain Metastases and Treatment
- Signaling Pathways in Disease
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Art, Aesthetics, and Perception
- Hereditary Neurological Disorders
- Cancer Immunotherapy and Biomarkers
- Peripheral Nerve Disorders
- Art, Politics, and Modernism
- Cancer-related cognitive impairment studies
- Peripheral Neuropathies and Disorders
- Cellular transport and secretion
Medizinische Hochschule Hannover
2021-2023
Abstract Background Oncological patients can benefit substantially from treatment with immune checkpoint inhibitors (ICI). However, there is a growing awareness of immune‐related adverse events (irAE). Especially ICI‐mediated neurological (nAE(+)), are tough to diagnose and biomarkers identify at risk missing. Methods A prospective register prespecified examinations was established for ICI treated in December 2019. At the time data cut‐off, 110 were enrolled completed clinical protocol....
IgPro20 is the first approved subcutaneous immunoglobulin (SCIg) preparation for treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Two different doses SCIg were investigated in pivotal PATH study. Real-world data, and particularly efficacy an equivalent dose switch from intravenous (IVIg) to SCIg, are still not available.In this prospective observational study, 41 CIDP treated changed (1:1) 1 week after last IVIg treatment. Patients examined at time 3 6...